Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Titel:
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study
Auteur:
Karasik, Avraham Lanzinger, Stefanie Chia-Hui Tan, Elise Yabe, Daisuke Kim, Dae Jung Sheu, Wayne H-H Melzer-Cohen, Cheli Holl, Reinhard W. Ha, Kyoung Hwa Khunti, Kamlesh Zaccardi, Francesco Subramanian, Anuradhaa Nirantharakumar, Krishnarajah Nyström, Thomas Niskanen, Leo Linnemann Jensen, Majken Hoti, Fabian Klement, Riho Déruaz-Luyet, Anouk Kyaw, Moe H. Koeneman, Lisette Vistisen, Dorte Carstensen, Bendix Halvorsen, Sigrun Langslet, Gisle Fazeli Farsani, Soulmaz Patorno, Elisabetta Núñez, Júlio